Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2

AIMS: Residual beta cell function in type 1 diabetes (T1D) is associated with lower risk of complications. Autoantigen therapy with GAD-alum (Diamyd) given in 3 intralymphatic injections with oral vitamin D has shown promising results in persons with T1D carrying the human leukocyte antigen (HLA) DR...

Descripción completa

Detalles Bibliográficos
Autores principales: Nowak, Christoph, Lind, Marcus, Sumnik, Zdenek, Pelikanova, Terezie, Nattero-Chavez, Lía, Lundberg, Elena, Rica, Itxaso, Martínez-Brocca, Maria A, Ruiz de Adana, MariSol, Wahlberg, Jeanette, Hanas, Ragnar, Hernandez, Cristina, Clemente-León, Maria, Gómez-Gila, Ana, Ferrer Lozano, Marta, Sas, Theo, Pruhova, Stepanka, Dietrich, Fabricia, Puente-Marin, Sara, Hannelius, Ulf, Casas, Rosaura, Ludvigsson, Johnny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721339/
https://www.ncbi.nlm.nih.gov/pubmed/35665810
http://dx.doi.org/10.1210/clinem/dgac343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721339/
https://www.ncbi.nlm.nih.gov/pubmed/35665810
http://dx.doi.org/10.1210/clinem/dgac343

Ejemplares similares